Antibody–drug conjugate I-DXd shows meaningful response in patients with extensive-stage ...
I-DXd, a B7-H3–directed antibody–drug conjugate, showed clinically meaningful responses in pretreated ES-SCLC patients, with a confirmed ORR of 54.8% at 12 mg/kg and 26.1% at 8 mg/kg doses. The 12-mg/kg dose was selected as optimal for further study.
Related Clinical Trials
Highlighted Terms
Related News
I-DXd, a B7-H3–directed antibody–drug conjugate, showed clinically meaningful responses in pretreated ES-SCLC patients, with a confirmed ORR of 54.8% at 12 mg/kg and 26.1% at 8 mg/kg doses. The 12-mg/kg dose was selected as optimal for further study.
Heavily pretreated ES-SCLC patients benefited from ifinatamab deruxtecan (I-DXd), with a 12 mg/kg dose showing higher overall response rate (54.8%) vs. 8 mg/kg (26.1%). Disease control rates were over 80% in both groups, suggesting I-DXd's potential as a treatment option for ES-SCLC.
I-DXd showed efficacy in heavily pretreated ES-SCLC patients, with 12 mg/kg dose achieving 54.8% ORR vs. 26.1% for 8 mg/kg. Safety profile consistent, but TEAEs more frequent at higher dose. 12 mg/kg selected as optimal for further studies.